Ovid Therapeutics Appoints New CEO, Dr. Amit Patel

TL;DR

Ovid Therapeutics just named Dr. Amit Patel as CEO, replacing Dr. Jeremy Levin.

AI Summary

Ovid Therapeutics Inc. announced on June 27, 2024, that its Board of Directors has appointed Dr. Amit Patel as Chief Executive Officer, effective immediately. Dr. Patel, who previously served as Chief Medical Officer, will also join the Board of Directors. The company also announced the departure of its previous CEO, Dr. Jeremy Levin, and the appointment of Dr. Sophia Hu as Chief Medical Officer.

Why It Matters

This leadership change at Ovid Therapeutics could signal a shift in the company's strategic direction and focus, potentially impacting its drug development pipeline and future performance.

Risk Assessment

Risk Level: medium — Leadership changes can introduce uncertainty regarding strategy and execution, impacting investor confidence and company performance.

Key Players & Entities

• Ovid Therapeutics Inc. (company) — The company filing the report.
• Dr. Amit Patel (person) — Newly appointed Chief Executive Officer and Board Member.
• Dr. Jeremy Levin (person) — Departing Chief Executive Officer.
• Dr. Sophia Hu (person) — Newly appointed Chief Medical Officer.
• June 27, 2024 (date) — Effective date of the leadership changes.

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share OVID The Nasdaq Stock Mar
• $4.0 m — workforce reduction to be approximately $4.0 million, which represents cash expenditur

Filing Documents

• d822326d8k.htm (8-K) — 29KB
• 0001193125-24-172225.txt ( ) — 150KB
• ovid-20240627.xsd (EX-101.SCH) — 3KB
• ovid-20240627_lab.xml (EX-101.LAB) — 18KB
• ovid-20240627_pre.xml (EX-101.PRE) — 11KB
• d822326d8k_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements, including, but not limited to, statements related to the results of the workforce reduction, any estimated charges associated with the workforce reduction and expectations regarding the Company's cash runway. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, impediments to the Company's ability to execute the workforce reduction as currently contemplated, the actual charges associated with the workforce reduction being higher than anticipated or changes to the assumptions on which the estimated charges associated with the workforce reduction are based, the Company's ability to achieve projected cost savings in connection with the workforce reduction, unintended consequences from the workforce reduction that impact the Company's business, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, risks related to the Company's ability to achieve its financial objectives, the risk that the Company may not be able to realize the intended benefits of its technology or its business strategy, or risks related to the Company's ability to identify business development targets or strategic partners, to enter into strategic transactions on favorable terms, or to consummate and realize the benefits of any business development transactions, the sufficiency of the Company's cash resources and anticipated cash runway, including the risk that the Company could utilize its available capital resources sooner than it currently expects, and the Company's need for additiona

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OVID THERAPEUTICS INC. Date: June 28, 2024 By: /s/ Jeffrey Rona Chief Business and Chief Financial Officer